KRSA (KRSA) R&D Ratio: Latest Data, Historical Trends & Peer Comparison
What is KRSA's (KRSA) R&D Ratio?
For the trailing twelve months (TTM) ended Dec 31, 2025, KRSA R&D Ratio was 46.24%, representing a -- change year over year.
For fiscal Q4'25 ended Dec 31, 2025, KRSA R&D Ratio was 50.63%, representing a +1532.94% change year over year.
For fiscal FY'25 ended Dec 31, 2025, KRSA R&D Ratio was 46.24%, representing a +223.35% change year over year.
R&D Ratio Historical Trend for KRSA
View KRSA's annual, quarterly, and TTM R&D Ratio data from 2019 to 2025, including historical growth rates and trend analysis.
KRSA TTM Data
| Metric | Q2'20Jun 30, 2020 | Q3'20Sep 30, 2020 | Q4'20Dec 31, 2020 | Q1'21Mar 31, 2021 | Q2'21Jun 30, 2021 | Q3'21Sep 30, 2021 | Q4'21Dec 31, 2021 | Q1'22Mar 31, 2022 | Q2'22Jun 30, 2022 | Q3'22Sep 30, 2022 | Q4'22Dec 31, 2022 | Q1'23Mar 31, 2023 | Q2'23Jun 30, 2023 | Q3'23Sep 30, 2023 | Q3'25Sep 30, 2025 | Q4'25Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R&D Ratio YoY | 1.59K% -- | 1.78K% -- | 2.46K% -- | 3.55K% -- | 1.28K% -19.4% | 1.11K% -37.85% | 954.74% -61.14% | 855.74% -75.88% | 1.97K% +54.49% | 2.42K% +118.22% | 1.94K% +102.99% | 2.79K% +226.32% | 2.66K% +34.89% | 2.12K% -12.29% | 17.37% -- | 46.24% -- |
KRSA Quarterly Data
| Metric | Q2'19Jun 30, 2019 | Q3'19Sep 30, 2019 | Q4'19Dec 31, 2019 | Q1'20Mar 31, 2020 | Q2'20Jun 30, 2020 | Q3'20Sep 30, 2020 | Q4'20Dec 31, 2020 | Q1'21Mar 31, 2021 | Q2'21Jun 30, 2021 | Q3'21Sep 30, 2021 | Q4'21Dec 31, 2021 | Q1'22Mar 31, 2022 | Q2'22Jun 30, 2022 | Q3'24Sep 30, 2024 | Q4'24Dec 31, 2024 | Q1'25Mar 31, 2025 | Q2'25Jun 30, 2025 | Q3'25Sep 30, 2025 | Q4'25Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R&D Ratio YoY | 1.58K% -- | 1.59K% -- | 1.40K% -- | 1.66K% -- | 1.84K% +16.39% | 3.43K% +114.81% | 9.09K% +551.04% | 13.05K% +686.59% | 401.80% -78.18% | 2.02K% -41.01% | 1.96K% -78.42% | 1.37K% -89.5% | 3.34K% +731.06% | 41.75% -- | 3.10% -- | 44.44% -- | 60.22% -- | 39.77% -4.75% | 50.63% +1532.94% |
KRSA Annual Data
| Metric | FY'19Dec 31, 2019 | FY'20Dec 31, 2020 | FY'21Dec 31, 2021 | FY'22Dec 31, 2022 | FY'24Dec 31, 2024 | FY'25Dec 31, 2025 |
|---|---|---|---|---|---|---|
R&D Ratio YoY | 2.11K% -- | 2.46K% +16.4% | 954.74% -61.14% | 2.01K% +110.86% | 14.30% -- | 46.24% +223.35% |
KRSA (KRSA) : Definition & Explanation
R&D Ratio shows how large a key operating expense is relative to revenue. It gives investors a quick read on where the company is spending to run, defend, or grow the business.
It matters because r&d ratio can help explain why margins are improving or weakening. In some businesses, a higher ratio can reflect pressure, while in others it can reflect deliberate investment.
This is usually calculated by dividing a reported expense line by revenue for the same period.
Investors usually read r&d ratio alongside revenue growth, gross margin, operating margin, and management commentary. The best interpretation depends on whether the spending is supporting future growth or simply offsetting weaker operating conditions.
KRSA (KRSA) R&D Ratio vs Competitors | Chemical Pharmaceuticals Comparison
Compare KRSA's (KRSA) R&D Ratio with competitors. View latest market cap and R&D Ratio performance.
| Ticker | Company | Market Cap | R&D Ratio |
|---|---|---|---|
| LLY | Eli Lilly | 1.08T | 19.53% |
| JNJ | Johnson & Johnson | 651.20B | 15.42% |
| ABBV | Abbvie | 466.55B | 15.12% |
| NVS | Novartis | 267.85B | 20.46% |
| NVO | Novo Nordisk | 190.81B | 15.85% |
| BMY | Bristol-Myers Squibb | 128.36B | 21.33% |
| SNY | Sanofi | 104.75B | 16.45% |
| GSK | GSK | 103.28B | 23.63% |
| TAK | Takeda Pharmaceutical | 60.21B | 15.21% |
| TEVA | Teva Pharmaceutical | 45.71B | 5.69% |
| ONC | Beone Medicines | 40.19B | 38.42% |
| RPRX | Royalty Pharma | 33.88B | 9.41% |
| VTRS | Viatris | 19.68B | 6.82% |
| JAZZ | Jazz Pharmaceuticals | 15.83B | 17.73% |
| NBIX | Neurocrine Biosciences | 15.43B | 33.80% |
| EXEL | Exelixis | 14.49B | 34.21% |
| CORT | Corcept Therapeutics | 12.42B | 33.86% |
| MDGL | Madrigal | 12.35B | 40.00% |
| AXSM | Axsome Therapeutics | 11.22B | 26.99% |
| RDY | Dr. Reddy'S Laboratories | 10.17B | 7.12% |
| ALKS | Alkermes | 7.84B | 22.75% |
| BLTE | Belite Bio | 6.86B | -- |
| RYTM | Rhythm | 6.82B | 79.24% |
| MIRM | Mirum | 6.42B | 169.30% |
| BLCO | Bausch + Lomb | 5.99B | 7.41% |
| AMRX | Amneal | 5.84B | 6.06% |
| LGND | Ligand | 5.68B | 12.11% |
| DFTX | Definium | 5.20B | -- |
| AMLX | Amylyx | 4.26B | -- |
| TLX | Telix | 4.25B | 21.31% |
KRSA (KRSA) R&D Ratio Related Metrics
Explore key financial metrics related to KRSA's (KRSA) R&D Ratio. Click on the links below to dive deeper into similar and complementary indicators.
About KRSA (KRSA)
KRSA
Industry
--
Established Date
--
Listing Date
--
Exchange
--
Full-time Employees
--
Fiscal Year Ends
--
Website
--
Security Type
--
Office address
--
Business
--
Introduction
--